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Abstract
Background: Mortality in patients with end-stage renal disorders is often a consequence of cardiovascular
complications. Renal replacement therapies may contribute to this morbidity by promoting cellular activation. In
renal failure patients peripheral blood samples were investigated for platelet and endothelial cell activation markers
to compare the effects of haemodiafiltration (HDF) and haemodialysis (HD).
Methods: Overall 28 patients were included in the study. Platelet P-selectin and leukocyte - platelet heterotypic
aggregates were studied by flow cytometry. Soluble P- and E-selectin values were determined by ELISA, while von
Willebrand factor (vWF) antigen levels were measured by immunoturbidimetry. Statistical analysis was done by the
SPSS v22 software.
Results: Platelet surface P-selectin was below 3.0 % in healthy controls, but it was higher during the dialysis after
4 h, 8 % and 14.3 % in HDF and HD, respectively. Monocyte-platelet heterotypic aggregates were significantly
elevated after 4 h in both treatments, up to 69.2 % in HDF and to 82.9 % in HD. Soluble P-selectin levels were also
significantly elevated by the end of both treatment procedures (p < 0.001), vWF antigen values, however, showed
elevation only during HD treatment.
Conclusions: The attenuated platelet activating effects of HDF compared to HD may contribute to a less
unfavourable vascular effect in this treatment modality.
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Background
Patients with end-stage renal disease (ESRD) undergo
renal replacement therapy to avoid fatal complications of
uremic toxins, elevated potassium level and overhydration.
Renal replacement therapy involves mostly haemodialysis
and in smaller proportion peritoneal dialysis treatments.
Recent technological advancements have significantly
contributed to improved efficacy of dialysis treatments. In
the clearance of waste products, the basic modality is
haemodialysis, where blood is cleared by the counter-flow
of the dialysis fluid by the effect of diffusion. Despite ad-
vancements in ESRD treatment, the 3-year mortality in
this patient group is 50 %, which is primarily contributed
to cardiovascular complications [1].
Haemodiafiltration (HDF) was introduced in the mid
seventies and was developed to increase the clearance of
substances with middle molecular weight and the physical
background of this modality is the convective transport. It
is widely used in Europe, with limited use in Japan or
Australia and is not approved in the United States, mostly
due to concerns of appropriate water quality, since in this
treatment the substitution fluid is reinfused into the
patient [2]. Nevertheless, several studies have reported im-
proved survival of patients on HDF versus HD in recent
years, if substitution fluid volume is higher than 18 L per
session [3–5].
Numerous authors have addressed the question of
coagulation and platelet activation in haemodialysed pa-
tients. One important finding is that cardiovascular
events were linked to the tissue factor (TF) system [6]
and that in ESRD patients an elevated level of monocyte
expressed TF along with other adhesion molecules like
* Correspondence: kappelmayer@med.unideb.hu
2Department of Laboratory Medicine, University of Debrecen, Nagyerdei krt.
98, Debrecen, Hungary
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Becs et al. BMC Nephrology  (2016) 17:147 
DOI 10.1186/s12882-016-0364-x
CD11b/18 were reported. This was even more pronounced
in ESRD patients under haemodialysis [7]. Both of these re-
ceptors contribute considerably to the procoagulant poten-
tial of blood. In previous studies dealing with extracorporeal
circulation, we also identified significant leukocyte activation
by investigating the same receptors involved in blood coagu-
lation initiation [8, 9]. Several studies have dealt with platelet
activation in HD patients describing aspects of platelet
count and function [10, 11] as well as prothrombotic
changes in platelet, endothelial and coagulation systems
[12], but only one paper addressed the question of platelet
activation in HD versus HDF and the results were published
as a side study of the CONTRAST trial [13]. These authors
described enhanced platelet-associated activation markers in
HDF patients, but decreased degranulation of platelets as
measured by the soluble marker beta-thromboglobulin [13],
consequently the cellular and soluble marker results were
somewhat contradictory.
Here, we investigated - in the same set of ESRD
patients - the effect of two different renal replacement
therapies on platelet and endothelial activation, by inves-
tigating cell-associated and soluble markers.
Methods
Patient enrolment and dialysis procedures
Twenty-eight patients with ESRD were selected for an
interventional longitudinal non-randomized study, each
subject qualified as its own control. Exclusion criteria in-
cluded diabetes mellitus, as this condition may cause
platelet activation. Similarly patients with cancer, haem-
atological or haemostasis disorders were excluded. Fur-
thermore, any patient on anti-platelet drugs was also
excluded. The Ethics Committee of the University of Deb-
recen approved the study protocol. The patients – after
receiving detailed information about the trial – gave writ-
ten informed consent. The age of participants was be-
tween 18 and 70 (13 males, 15 females, mean age 53 ±
13.8 years), and each patient was on dialysis for at least
3 months before the study was started (mean length 89.5
± 74.5 months).
The patients underwent dialysis three times a week
employing Fresenius 5008S devices (Fresenius Medical
Care, Bad Homburg, Germany), and one session lasted for
250 min (to reach the expected efficiency in 5 cases the
treatment lasted for 270 min, but the blood sampling also
took place after 4 h). Cordiax FX dialysers, FX60, FX600
and FX800 respectively were used (Fresenius) for the treat-
ments, which were matched to patients weight and blood
flow rate as the effectiveness required it. Effectiveness was
calculated during each treatment employing Online
Clearance Monitoring Kt/V (OCM Kt/V; Fresenius Medical
Care, Bad Homburg, Germany) measurements. OCM Kt/V
should be higher, than 1.3 in hemodialysis and more than
1.4 during haemodiafiltration. Haemodiafiltration was
performed with the average Kt/V of 1.67 ± 0.21, while only
1 patient could not reach the target. In hemodialysis the
Kt/V value was 1.48 ± 0.2 on average and 3 patients were
under 1.3. In most cases the FX60 with 1.4 m2 was optimal
(24 patient). In order to provide efficient dialysis we
employed FX600 for 3 patients with dialyser surface of
1.6 m2 or FX800 for 1 patient with 2.0 m2. The type of
dialysers was not changed during the study between the
modalities. Cordiax FX membranes represent the latest
Helixone®plus membranes with INLINE steam sterilization
assuring excellent biocompatibility. The same speed of
blood flow (mean 366.1 ± 63.7 mL per minute) and dialys-
ate flow (439.3 ± 76.5 mL per minute) was used in both
modalities. In order to remove the excess fluid the net
ultrafiltration during haemodialysis and haemodiafiltration
was 2703.6 ± 1118.0 mL per session and 2432.1 ±
1014.4 mL per session, respectively. At our dialysis centre
we use HDF as the standard modality, so in the beginning
of our study we started the sampling with this method. To
avoid any disturbing factor we waited for 2 weeks after
switching to HD before measuring the platelet markers in
HD treatment. Avoiding any influence of anticoagulation
we used the same amount of unfractionated heparin during
both types of treatments. The heparin dose was adjusted to
the patient’s need to avoid blood line coagulation and
bleeding from AV-fistules. In all cases heparinization was
stopped 30 min before the end of the session. During hae-
modiafiltration the volume of substitution fluid was 23.4 ±
3.8 l. The substitution fluid was prepared on-line from dia-
lysis solution through a set of two membranes to purify it
before direct infusion into the blood line. The substitution
fluid was manufactured on-line from ultrapure water and
consisted of 138 mmol/L sodium, 2 or 3 mmol/L potassium
depending on the patient’s potassium value, 1.25 mmol/L
calcium, 0.5 mmol/L magnesium, and 1 g/L glucose.
A two-week adjustment period was chosen before the
treatment modality was switched for HD and the
samples were collected from the same patients again.
The bicarbonate dialysis solution contained the same
amount of solutes as described above. Bicarbonate
concentration of dialysate/replacement fluid was
adjusted between 28–38 mmol/L to obtain plasma bi-
carbonate level of 20–22 mmol/L prior to dialysis.
The purity and sterility of dialysis and substitution
fluids met the criteria of the 8th edition of European
Pharmacopoeia (endotoxin level <0.01 EU/mL, bacter-
ial counts <0.1 CFU/mL and any heavy metal ions
<0.01 mg/L).
Blood collection and cell counting
Blood samples were taken from the efferent line port
into sodium citrated tubes (3.2 %, BD Vacutainer) at
three time points, at 4 min, 1 and 4 h after the onset of
dialysis. In contrast to see the exact activation in the
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beginning we dedicatedly took 0 min samples from ar-
terial needles and 4 min samples from efferent line only
in ongoing HDF treatments. Cell counting was carried
out by the Advia 2120 Haematology Analyzer (Siemens,
Dublin, Ireland) within two hours of blood collection and
cell numbers were adjusted for the haemoconcentration
by using the red blood cell counts.
Platelet poor plasma (PPP) preparation and measurement
of soluble markers
Whole blood was centrifuged at 1500 x g for 15 min at
room temperature, albumin levels were immediately
measured by a Cobas C8000 Clinical Analyzer (Roche
Diagnostics, USA). Soluble P-selectin and E-selectin
levels were measured by a commercial ELISA kit (R&D
Systems, Minneapolis, MN, USA) according to the man-
ufacturer’s instructions, while von Willebrand Factor
(vWF) antigen levels were measured by turbidimetry
(BCS XP, Siemens, Germany). Levels of soluble proteins
were adjusted for the haemoconcentration by normaliz-
ing the results for albumin values.
In randomly selected patients who underwent HDF, hep-
arin content of plasma was measured based on the activated
factor X (anti-Xa) inhibitory assay (Berichrom® Heparin,
Siemens). This is a chromogenic assay for the determination
of the activity of heparin (conventional or low-molecular-
weight) in plasma. Factor Xa is inactivated by antithrombin
III (AT III) during the incubation phase of the test and the
reaction is catalyzed by heparin. The quantity of residual
FXa is determined via the increase in absorbance at 405 nm,
using a chromogenic substrate in a kinetic test.
Flow cytometric assays
The expression of platelet surface P-selectin and
leukocyte - platelet heterotypic aggregates were mea-
sured by flow cytometry (FC500 flow cytometer, Beck-
man Coulter). To standardize measurement conditions
and to minimize in vitro platelet activation whole blood
was fixed for P-selectin measurement and labelled for
heterotypic aggregate determination within 2 h after
blood collection. After fixation and washing by PBS,
samples were labelled by CD42a-FITC and CD62-PE
(Becton Dickinson Biosciences) for 20 min, washed twice
and analyzed. Whole blood samples were incubated with
CD14-PE and CD42a-FITC for 15 min to detect
leukocyte-platelet heterotypic aggregates. Results were
always compared to samples stained with non-immune
IgG that served as isotype controls. Red blood cells were
lysed and the samples were washed twice and fixed and
subsequently analyzed.
Statistical analysis
Kolmogorov-Smirnov test was used for the evaluation of
the normality of the data. Most parameters were non-
normally distributed; univariate analyses were performed
by Mann–Whitney U-test or the independent samples
t-test. For paired analyses, as required for the related
samples, Wilcoxon signed ranks test or the paired-
samples t-test were performed. The Spearman’s ρ value
was calculated for correlation analysis. All analyses
were performed using the SPSS Statistics software, ver-
sion 22.0 (IBM Corps., Armonk, NY, USA).
Results
Evaluation of the changes during dialysis
Both dialysis procedures cause a considerable fluid loss,
thus there is a variable degree of haemoconcentration that
was monitored by measuring the red blood cell (RBC)
count and albumin values at each sampling time. The in-
crease in RBC counts and albumin were significant be-
tween sampling times (Additional file 1: Figure S1), by
using both treatment modalities. Thus, cell counts were
normalized for RBC and soluble markers were normalized
for albumin values. Platelet counts - adjusted for the hae-
moconcentration - significantly decreased during the four-
hour observation period that suggests a considerable
sequestration of these cells, most likely on the dialyzer
surface (Additional file 2: Figure S2).
Direct platelet activation markers
Platelet P-selectin values were well over the reference
range of < 3 %, as described earlier [14], right from the
beginning of the dialysis procedures (Fig. 1 panels a, b).
It needs to be emphasized that the treatment requires
the dialyzer to be filled up with heparinized blood, and
this is achieved by a 4–5 min roller pump-assisted extra-
corporeal circulation. As such, a few minutes have
already elapsed when the initial sample (0 h) was
collected. HD treatment resulted in higher platelet P-
selectin values when compared to the HDF procedure
and the difference was the largest by the end of the pro-
cedure (Table 1). Although the median soluble P-selectin
(sP-selectin) values were within the reference range by
the end of both procedures, several results exceeded the
upper reference limit (Fig. 1 panels c, d). The sP-selectin
values increased during the procedure, but significant
differences were observed between the two treatment
modalities at the 1 h time-point, with the values being
higher during HDF (Table 1).
Platelet-leukocyte aggregates
Platelet activation was also monitored by using the
indirect platelet activation tests where we examined
heterotypic cell aggregates. Here, a striking elevation was
observed when monocyte-platelet aggregates were ana-
lyzed compared to a mean value of 38 % obtained in con-
trols and previously published by us and others [15, 16].
The ratio of these aggregates kept increasing during the
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dialysis and the number of these aggregates were signifi-
cantly higher in HD treatment at each analysis time point
(Fig. 2a, b) and a similar tendency could be observed in
case of neutrophil-platelet aggregate ratio during dialysis
(Fig. 2c, d). At each sampling time point HD treatment re-
sulted in significantly higher monocyte-platelet aggregate
formation than HDF treatment.
Control measurements
Since the above elevations were significant, we set out to
determine the effect of potential variables on the studied
direct and indirect platelet activation markers. First, we
investigated the effect of blood flow rate. At 0 h, in the
HD and the HDF groups, blood flow rate did not correl-
ate with the studied platelet activation markers (surface
P-selectin, soluble P-selectin, monocyte, and neutrophil
heterotypic aggregate). In the HD and the HDF groups,
the blood flow rate also did not correlate with the per-
centage change between the 0 and 4 h values of the
studied platelet activation markers, thus we can con-
clude, that the observed alterations are not related to
blood flow rate. Furthermore, platelet activation markers
showed no correlation with the duration of treatment
months of renal replacement therapy. Subsequently, we
introduced another set of measurements where we hy-
pothesized that the high platelet activation markers ob-
served already in the 0 h samples could be due to platelet
and/or leukocyte activation during the initial minutes
when the dialysis system was filled up (these were the pre-
dialysis samples). Indeed in this series of measurements,
we observed that there was a significant decrease in plate-
let and leukocyte counts between predialysis and 0 h sam-
ples (Fig. 3a, b), furthermore, platelet activation markers
were also increased in the 0 h samples compared to the
predialysis samples (Fig. 3c, d).
Since heparin may also activate platelets, we thought
to examine whether the observed changes in platelet ac-
tivation markers could be elicited by the heparin utilized
during these treatments. To determine the effects of
heparin on platelet activation markers in ESRD patients
during dialysis, we conducted an experiment in which
we added in vitro unfractionated heparin (UFH) to the
predialysis samples from 3 ESRD patients in a range of
heparin concentrations as determined by the anti-Xa
assay. Samples were incubated with 0.5 U/mL or 2.0 U/
mL UFH for 5 or 60 min. The surface expression of P-
selectin and the leukocyte-platelet heterotypic aggregates
were measured by flow cytometry and the results were
Fig. 1 Changes in platelet P-selectin (a and b) and soluble P-selectin (c and d) during haemodiafiltration (HDF) and haemodialysis (HD) at 0, 1
and 4 h. The shaded area represents the reference range for the respective parameter on this and subsequent figures. P values were calculated
by Wilcoxon signed ranks test
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Table 1 P values upon comparing the studied parameters at 0, 1 and 4 hours during haemodiafiltration (HDF) and haemodialysis (HD). n.s.: p > 0.05
Parameters 0 hour 1 hour 4 hour
HD (mean ± SEM) HDF (mean ± SEM) P value HD (mean ± SEM) HDF (mean ± SEM) P value HD (mean ± SEM) HDF (mean ± SEM) P value
Platelet P-selectin (%) 8.26 ± 0.98 6.5 ± 0.84 n.s. 12.00 ± 1.33 9.50 ± 1.11 n.s. 14.45 ± 1.92 7.56 ± 1.07 p < 0.001
Soluble P-selectin (ng/mL) 33.68 ± 1.99 38.26 ± 2.17 n.s. 36.08 ± 2.28 45.07 ± 2.75 p = 0.022 39.22 ± 2.40 46.15 ± 3.26 n.s.
Monocyte-platelet aggregate (%) 64.82 ± 3.57 47.61 ± 2.57 p < 0.001 76.79 ± 3.06 65.82 ± 3.28 p = 0.010 83.18 ± 2.52 67.79 ± 3.48 p = 0.001
Neutrophil-platelet aggregate (%) 13.75 ± 1.73 9.54 ± 0.84 p = 0.024 17.96 ± 1.81 15.29 ± 1.62 n.s. 24.46 ± 2.57 19.50 ± 2.92 p = 0.032
Soluble E-selectin (ng/mL) 24.75 ± 2.42 25.58 ± 2.14 n.s. 25.08 ± 2.75 26.46 ± 2.09 n.s. 24.37 ± 2.24 25.54 ± 2.07 n.s.
vWF antigen (%) 158.60 ± 10.25 158.30 ± 9.31 n.s. 161.40 ± 10.82 166.10 ± 9.93 n.s. 169.80 ± 10.69 162.80 ± 10.66 n.s.
P values were calculated by Wilcoxon signed ranks test
Becs
et
al.BM
C
N
ephrology
 (2016) 17:147 
Page
5
of
10
compared to non heparinized samples. In vitro
heparinization did not augment the level of the activa-
tion marker of platelets neither the amount of hetero-
typic aggregates (Additional file 3: Figure S3).
Endothelial cell activation
Since endothelial injury has also been described during
extracorporeal circulation we measured two endothe-
lium associated biomarkers the soluble E-selectin (sE-
selectin) and the vWF antigen. At each sampling time,
there were only few sE-selectin values above the manu-
facturer suggested upper reference limit (51 ng/mL),
however the median sE-selectin was not elevated during
the procedures and there were no difference between
treatment modalities. Also, no difference was observed
between dialysis procedures for vWF antigen, in contrast
to sE-selectin but vWF antigen values were elevated
(>150 %) right from the beginning and significantly in-
creased by the end of the HD procedure (Fig. 4).
Discussion and conclusions
In summary of our present study we found novel changes
in platelet activation markers during the two different dia-
lysis treatment modalities. Platelet and soluble P-selectin
values demonstrated increasing levels during the treat-
ments, but there were a few significant differences when
the two modalities were compared. Heterotypic aggregate
formation was also elevated during both modalities
especially in HD. Monocyte-platelet aggregates showed
significantly higher levels during HD compared to HDF.
Changes in neutrophil-platelet aggregates showed increas-
ing levels in a time-dependent manner but with only lower
significancy levels. Endothelial activation markers, such as
E-selectin and von Willebrand factor, were observed in
HD group and only vWF elevation was significant during
the treatments.
Individual data from our work according to previous
studies and literature can make a more complex view of
haemostatic abnormalities in chronic kidney diseases,
since in this patient group both bleeding and thrombotic
complications are observed and this dual effect is also
characteristic for platelets. In CKD patients, platelet
dysfunction is frequently observed that may be caused
by the uremic toxins, enhanced nitric oxide production
and anaemia, but the platelets of dialyzed patients are
constantly activated and these repeated procedures re-
sult in the ’exhausted platelet syndrome’ [17, 18]. Even
in early reports it was described, that platelet-leukocyte
Fig. 2 Changes in monocyte-platelet aggregates (a and b) and neutrophil-platelet aggregates (c and d) during haemodiafiltration (HDF) and haemodialysis
(HD) at 0, 1 and 4 h. Wilcoxon signed ranks test was employed to calculate p values
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aggregates occur during dialysis, most likely related to
the primary platelet activation [19]. Already at this time
the authors suggested this test as a biocompatibility
marker. Further studies identified platelet trapping,
particularly sequestration of the larger platelets in the
circuit, and suggested that soluble markers like beta-
thromboglobulin are suitable for detecting platelet de-
granulation [20]. Another methodological approach to
investigate platelet activation was published by Schoorl
and colleagues, who verified platelet degranulation by
light and electron microscopy [21]. Nevertheless, in
more recent reports the biocompatibility of the dialyzer
membranes was monitored by the platelet count and it
was concluded, that the more biocompatible newer
membranes like the polysulfones do not result in marked
thrombocytopenia [22]. In our studies we found by using
a highly biocompatible membrane, that the platelet
count did not change dramatically however, a significant
platelet count decrease was observed with both treat-
ment modalities.
In addition to platelet activation, leukocyte activation
may occur during HD and contribute to heterotypic ag-
gregate formation. CKD patients are exposed persistently
to a low-grade inflammation. The level of inflammatory
markers is affected by numerous factors such as transient
infections, several comorbidities, and the intermittent
stimulus of the dialysis procedure [23]. The archetype in-
flammatory marker, C-reactive protein, has long been
shown to be able to elicit procoagulant functions by
stimulating monocyte tissue factor expression [24]. Fur-
thermore, the binding of activated platelets, to monocytes
and neutrophils, via P-selectin require P-selectin glycopro-
tein ligand 1 (PSGL-1) that has been shown to be redis-
tributed by activated cytokines [25].
We have identified that flow cytometry based assays
are the most sensitive in identifying platelet and/or
leukocyte activation, when comparing the two different
treatment modalities. The considerable elevation in the
gold-standard platelet P-selectin suggests that the very
high heterotypic aggregate rate between the myeloid
cells and platelets are largely due to primary platelet
activation as proposed recently [26]. This phenomenon
occurs very early during dialysis as significant elevations
could be observed after a few minutes of system filling
compared to baseline values. Since at this early time
point there is minimal recirculation this may have been
caused mostly by the enhanced turbulence. In previous
clinical conditions we also found augmentation com-
pared to controls in platelet P-selectin and the
monocyte-platelet ratio in obese and diabetic patients
and during coronary stenting [14, 15, 27]. However, the
degree of the elevation of these aggregates in such
Fig. 3 Changes in platelet count (a), white blood cell count (WBC) (b), platelet P-selectin (c) and monocyte-platelet aggregates (d) during haemodiafiltration
(HDF) at predialysis and 0 h. P values were calculated by Wilcoxon signed ranks test
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patient groups were well below that observed during our
present study on HD and HDF treatments. Although a
previous study has postulated a role for these aggregates
in the pathophysiology of vascular disorders e.g., the de-
velopment of aortic stiffness, the pathomechanism is still
to be elucidated [28]. Nonetheless, soluble factors are
likely to play a role in mediating platelet/leukocyte acti-
vation, since their effect may be propagated via the
plasma, probably by activating complement factors [29].
We previously identified that haemodiafiltration was
found to have beneficial effect on echocardiographic
markers representing left ventricular diastolic function
[30]. We investigated the changes in platelet activation
markers to evaluate the effect of different types of dialy-
sis treatments. In this present study on the comparison
of the two treatment modalities we also observed benefi-
cial effects on direct and indirect platelet activation
markers of HDF compared to HD. The dialysis was per-
formed using dialysers with different effective surface
area (FX60: 1.4 m2; FX600: 1.6 m2; FX800: 2.0 m2,
adjusted to the patient’s weight, dialysis efficiency, etc.)
and acknowledging the limitation of statistical analyses
with small sample sizes (FX60: 24 patients, FX600: 3 pa-
tients and FX 800: 1 patient), which in the present case
are way below the limit of safe statistical handling, we
found no statistically significant differences comparing
the 3 membrane surface groups.
Although in a previous meta-analysis a similar sensitivity
could be observed in vascular disorders for soluble and
platelet-associated P-selectin [31] the simultaneous investi-
gation of these markers during dialysis treatments showed
that platelet P-selectin is having a superior sensitivity com-
pared to soluble P-selectin. As was already suggested by
Michelson [32] probably the most sensitive platelet activa-
tion assay is the measurement of the monocyte-platelet
conjugates, as platelets may lose P-selectin in the circula-
tion. In our patient cohort, we found that such platelet-
leukocyte aggregates also had an excellent sensitivity as it
showed nearly maximal values that can usually be observed
only in agonist stimulated samples during in vitro experi-
ments. In contrast to platelet activation markers, the sol-
uble endothelial cell activation marker E-selectin did not
show any change in kinetics. E-selectin is synthesized de
novo in stimulated endothelial cells and its expression and
release requires considerable time. Unlike E-selectin, vWF
is stored in the endothelial Weibel-Palade bodies and can
readily be mobilized when the endothelial cells are acti-
vated. It is plausible that the elevated levels experienced
during the renal replacement therapies are a result of this
difference and most likely this is why in HD, vWF antigen
Fig. 4 Changes in soluble E-selectin (a and b) and von Willebrand Factor (vWF) antigen (c and d) during haemodiafiltration (HDF) and haemodialysis
(HD) at 0, 1 and 4 h. Wilcoxon signed ranks test was employed to calculate p values
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increased significantly by the end of the procedure. It
should also be noted that the Weibel-Palade bodies of acti-
vated endothelial cells can also release soluble P-selectin,
however even with this potential contribution, the sensitiv-
ity of this parameter was below that of the cell associated
markers. The molecular weights of measured markers of
platelet activation, such as E-selectin, P-selectin and vWF
antigen are 115 kDa, 140 kDa and 250 kDa (monomer),
respectively. The diameter of monocyte-platelet aggregates
is at least 15 μM. The Sieving coefficient of FX Cordiax®
dialysers for albumin is less, than 0.001 according to the
manufacturer’s description. Thus, these large molecular
weight substances are unable to cross the capillary
membrane in the dialysers.
Based on these observations, we propose that the
more gentle effects of HDF compared to HD may con-
tribute to a less unfavourable vascular effect in this treat-
ment modality. The underlying mechanism can be
explained by the fundamental physical processes during
dialysis treatment methods. Although both modality use
the same type of dialyser, with the same pore-size, while
HD employs only diffusion for excretion HDF is apply-
ing convective transport as well. Convective transport
alone can increase dramatically the excretion of small to
mid-size proteins with the molecular weight 5–40 kDa
and its also increases the excretion of smaller molecules
compared to HD. Further studies are required to deter-
mine whether the decreased platelet activation can be
explained by the increased elimination of the enhancers
of platelet activation during HDF.
Additional files
Additional file 1: Figure S1. Red blood cell count (panels A, B) and
albumin values (panels C and D) constantly increase during both
treatment modalities as a result of haemoconcentration. Paired-samples
t-test was employed for red blood cell count and Wilcoxon signed ranks
test for albumin to calculate p values. (TIF 104 kb)
Additional file 2: Figure S2. Platelet count is decreased as they are
sequestered during both procedures. Paired-samples t-test was employed
to calculate p values. (TIF 105 kb)
Additional file 3: Figure S3. No significant changes (n.s.) were observed
in platelet P-selectin (A), monocyte-platelet aggregates (B) and neutrophil-
platelet aggregates (C) at different concentrations of unfractionated heparin
(UFH) following 5 and 60 min of incubation. P values were calculated by
Wilcoxon signed ranks test. (TIF 189 kb)
Additional file 4: Raw data of the study. (XLSX 32 kb)
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